Get started
Author

Jennifer Wong

Observed names: J Wong, J. Wong, JENNIFER WONG, Jennifer Wong (21352357), WONG, Jennifer, Wong, Jennifer
Institution: Institut Curie
Observed institutions: Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Université Paris Sciences et Lettres, Université Paris-Saclay, Institut Gustave Roussy, Génomes, biologie cellulaire et thérapeutiques, Sorbonne Paris Cité, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, La Ligue Contre le Cancer, Assistance Publique – Hôpitaux de Paris, Institut de Cancérologie de Lorraine, Centre Léon Bérard, CRAN, Laboratoire de Biochimie, Centre Oscar Lambret, UniCancer Group, Hôpital Saint-Louis, Biologie cellulaire et Cancer, Université Paris Diderot, Institut Curie, Université de Lorraine, Nantes Université
ORCID: 0000-0002-1898-6539
Observed ORCID: 0000-0002-1898-6539
OpenAlex ID: A5103106946
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
2014 · C Le Tourneau, X Paoletti, et al. · British Journal of Cancer · 74
PDF
MDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-κ Transcript
2020 · Charles Cassius, Reyhan Amode, et al. · Journal of Investigative Dermatology · 70
Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis
2023 · Jacqueline Fontugne, Jennifer Wong, et al. · The Journal of Pathology · 30
PDF
Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
2023 · David Gentien, Elnaz Saberi-Ansari, et al. · Cell Reports · 24
PDF
The genomic and transcriptomic landscape of metastastic urothelial cancer
2024 · Yohann Loriot, Maud Kamal, et al. · Nature Communications · 23
PDF
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine
2024 · Célia Dupain, Tom Gutman, et al. · BMC Biology · 21
PDF
Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization
2021 · Thibault Passeri, Lorenzo Giammattei, et al. · Acta Neurochirurgica · 15
PDF
SegCorr a statistical procedure for the detection of genomic regions of correlated expression
2017 · Eleni Ioanna Delatola, Emilie Lebarbier, et al. · BMC Bioinformatics · 10
PDF
Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition
2025 · Peter N. Fiorica, Lisa Golmard, et al. · Clinical Cancer Research · 7
Molecular characterisation of tumours of the lacrimal apparatus
2023 · Roseline Vibert, Joanna Cyrta, et al. · Histopathology · 7
Mosaic BRCA1 promoter methylation contribution in hereditary breast/ovarian cancer pedigrees
2023 · Mathias Schwartz, Sabrina Ibadioune, et al. · Journal of Medical Genetics · 6
Correction to: Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization
2021 · Thibault Passeri, Lorenzo Giammattei, et al. · Acta Neurochirurgica · 6
PDF
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
2024 · Nicolas Jacquin, Ronan Flippot, et al. · npj Precision Oncology · 5
Nanopore sequencing as a cutting-edge technology for medulloblastoma classification
2024 · Mathilde Filser, Jacob Torrejon, et al. · Neuro-Oncology · 4
PDF
Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis
2025 · Célia Dupain, Nicolas Jacquin, et al. · The Lancet Regional Health - Europe · 3
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
2024 · K. Rahmani Narj Abadi, C. Dupain, et al. · ESMO Real World Data and Digital Oncology · 2
PDF
Mdb-12. Nanopore Sequencing as a Cutting-edge Technology for Medulloblastoma Classification
2024 · Mathilde Filser, Jacob Torrejon, et al. · Neuro-Oncology · 2
159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers
2021 · J. Lehmann-Che, J. Wong, et al. · Annals of Oncology · 2
First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma
2018 · JACQUELINE LEHMANN-CHE, CATHERINE MIQUEL, et al. · Anticancer Research · 2
PDF
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer
2024 · Yohann Loriot, Maud Kamal, et al. · Nature Communications · 1
PDF
Effect of national multidisciplinary tumor boards on diagnostic stratification and therapeutic management in cancers of unknown primary.
2023 · Nicolas Jacquin, Maud Kamal, et al. · Journal of Clinical Oncology · 1
PDF
Multi-stage pathological and immunohistochemical characterization of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced murine bladder cancer
2018 · J. Fontugne, J. Wong, et al. · European Urology Supplements · 1
SegCorr a statistical procedure for the detection of genomic regions of correlated expression
2015 · Delatola, Eleni Ioanna, Lebarbier, Emilie, et al. · arXiv (Cornell University) · 1
PDF
Abstract P1-08-27: Quantitative analysis of tumor expression of phosphoproteins from PI3-kinase and MAP-kinase signaling pathways as biomarkers of the biological and clinical activity of trastuzumab and everolimus in breast cancer: Unicancer RADHER phase II trial results
2013 · J-L Merlin, M Lion, et al. · Cancer Research · 1
Corrigendum to “Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis” The Lancet Regional Health – Europe, Volume 60, January 2026, 101524
2026 · Célia Dupain, Nicolas Jacquin, et al. · The Lancet Regional Health - Europe
Works count: 66
Citation count: 317
H-index: 8
I10-index: 8
Year
Topic
Type